Dr. Jenna Henderson, ND Subheadline  A clinical overview of kidney function changes with aging, common diagnostic pitfalls, ...

AstraZeneca’s Ultomiris met its primary endpoint in the Phase III I CAN trial for IgA nephropathy, significantly reducing proteinuria at 34 weeks. The result marks the first late-stage success for the ...

AstraZeneca’s Ultomiris met its first co-primary endpoint in a Phase III trial for IgA nephropathy, significantly reducing urine protein levels by week 34. The result supports the drug’s potential as ...

A six-fold risk surge in renal impairment among patients with concurrent type 2 diabetes and systemic hypertension highlights ...

Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...

Kidney relapse was associated with faster kidney function decline in patients with lupus nephritis. Kidney relapse appears to be a principal determinant of long-term kidney function loss in lupus ...

This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. More than one in seven people in the U.S. have ...

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Several years ago, nephrologists attempted a first-of-its-kind effort ...

A new national study evaluating a landmark U.S. transplant policy change finds that efforts to correct the harms of race-based kidney function equations are associated with increased kidney ...

Results show that it may be beneficial to add longitudinal monitoring of kidney function to the management of patients with MDS. Myelodysplastic syndromes (MDS) are associated with a substantially ...

Novartis NOVN-0.34%decrease; red down pointing triangle said its Vanrafia drug slows the decline in kidney function for adults with the progressive autoimmune kidney disease, IgA nephropathy (IgAN).